Objectives: Clinical trials of therapies for non-small cell lung cancer (NSCLC) are increasingly requiring mandatory tumor samples or research biopsies, both of which are potential barriers to trial participation. We assessed the impact of performance of research biopsies on the enrollment of patients with advanced NSCLC in clinical trials.
Results: Of the 55 clinical trials identified, 38 required tumor samples for enrollment. Six mandated repeat biopsies, whereas 32 permitted use of archival samples. Trial participation was offered to 636 patients at 940 unique study encounters, with some patients enrolling in multiple trials. Of the patients in 549 encounters during which participation in a therapeutic trial was offered, 60% received study treatment. More patients received study treatment (83% versus 55%, p < 0.0001) and study treatment was started earlier (after 9 days versus after 16, p ¼ 0.002) when the trial did not have a mandatory tissue sample requirement. A similar trend was noted for trials permitting use of archival tissue versus mandatory repeat biopsies. The most common barriers to trial enrollment included absence of a required biomarker (34%), withdrawal of consent (20%), deterioration or death (17%), other exclusion criteria (15%), and insufficient biopsy tissue (10%).
Conclusion:
A growing number of NSCLC trials are requiring tumor tissue for treatment eligibility, which appears to be a significant barrier to trial enrollment. Potential solutions include use of available diagnostic samples (e.g., cytology samples), development of peripheral blood assays for molecular markers, faster central laboratory testing turnaround time, and more resources for rapid biopsy.
Introduction
Lung cancer is the most common cancer worldwide and the leading cause of cancer deaths. An improved understanding of the molecular basis of non-small cell lung cancer (NSCLC), along with the development of molecularly targeted therapies, has led to major improvements in disease outcomes. 1 The effectiveness of agents targeting epidermal growth factor gene (EGFR)-mutant and anaplastic lymphoma kinase gene (ALK)-rearranged NSCLC has been well established, and molecular testing has become standard of care. [2] [3] [4] Further studies of next-generation targeted therapies for advanced NSCLC are ongoing.
Most patients with NSCLC have advanced or unresectable disease when first seen and often are investigated by using procedures such as bronchoscopic biopsy or computed tomography-guided percutaneous needle biopsy. 5 Such diagnostic procedures yield small histologic or cytologic samples that often are adequate for diagnosis of malignancy; frequently, however, little or no tissue remains for additional diagnostic studies. For patients who have had metastatic disease for an extended period of time, diagnostic biopsy samples taken months or years previously may not accurately reflect the current molecular profile of the patient's disease. 6 Many contemporary clinical trials of molecularly targeted therapy for NSCLC mandate performance of repeat research biopsies or submission of archival tumor tissue samples for analysis. 6 Although research biopsies may not result in direct personal benefit to the patient, they may be used for integral biomarker analysis to determine eligibility for a specific investigational therapy because treatment activity may be improved by molecular selection. Alternatively, research biopsies may be used for future exploration of predictive biomarkers to establish associations between molecular tumor features and clinical outcome. Such indications for tumor analysis apply to both repeat biopsies and analysis of archival tissue. The tension between exposing patients to the additional procedural risks of research biopsies for exploratory assays with unclear direct clinical benefit has led to ethical debate. Supporters argue that exploratory data obtained from research biopsies are critical to clarifying the mechanism of action of investigational agents and guiding treatment decisions for future patients. 7, 8 Opponents argue that mandatory research biopsies expose patients to risk with no direct clinical or scientific benefit, particularly in the setting of early phase trials. 9, 10 In addition, patients may perceive harm as a result of losing access to promising, even if unproven, experimental therapies if they are unable to undergo the research biopsies that are required for enrollment.
11
Despite this ethical debate, many clinical trials of therapies for advanced NSCLC now require mandatory biopsies or archival tissue. In this study, we assess the impact of mandatory tissue sample or biopsy requirements on enrollment in clinical trials of therapies for advanced NSCLC.
Methods

Study design and population
We reviewed the cases of patients with advanced NSCLC who had been evaluated for clinical trials of systemic therapy at the Princess Margaret Cancer Centre, a major comprehensive cancer center with a focus on clinical trials, from January 2007 to March 2015. Study coordinators tracked patients who had been screened for trials prospectively. The institutional research ethics board reviewed and approved this study.
Patients screened for phase I, II, and III systemic therapy trials were included. Patients screened for research molecular profiling also were included. Those screened only for radiation oncology, surgical or supportive care trials, observational studies, and surveys were excluded.
Objectives
The primary objective was to determine the impact of mandatory tumor tissue requirements in clinical trials on the proportion of patients with advanced NSCLC who subsequently enrolled in those trials and proceeded to receive study therapy. A secondary objective was to determine the impact of mandatory tumor tissue requirements on the time from initial consent to when a repeat biopsy sample was obtained and study therapy was started. Finally, we evaluated the reasons why patients screened for clinical trials were unable to proceed to study enrollment.
Data collection
Trial characteristics, including phase and tumor tissue requirement, were determined by reviewing study protocols (by C.L. and M.S.). The prospective data collected (by N.N., A.F., N.P.L., D.Z., M.S., T.P., C.L., and M.S.) included patient demographics, trial outcomes (including reasons why patients were excluded from or did not enroll in trials), and detailed timeline information (including time of initial consent, repeat biopsy, and initiation of study treatment). These data were confirmed in clinical notes (by C.L. and M.S.).
Data analysis
Descriptive analysis was used to summarize trial and patient characteristics. Fisher's exact test, the WilcoxonMann-Whitney test, and the Kruskal-Wallis test were performed where appropriate to test for differences among the groups. Statistical analysis was carried out using SAS v9.3 (Cary, NC).
Results
Trial characteristics
Overall, 55 trials were identified and included in this analysis ( Fig. 1 ). All trials were linked to investigational therapy except for one molecular profiling study that was not linked directly to therapy. The 54 trials with investigational therapy included 12 phase I, six phase I/II, 18 phase II, one phase II/III, and 17 phase III trials. Thirty-eight trials (69%) required tumor tissue for enrollment, whereas 17 had an optional or no tumor tissue requirement. Six trials (11%) mandated repeat biopsies (performed after patient consent for a trialspecific biopsy had been obtained), whereas archival samples were permitted for 32 trials. In the case of 24 trials, presence and/or confirmation of a prespecified biomarker was required for patients to receive investigational treatment. Two permitted use of cytology or fine-needle aspirate samples, whereas all the remaining trials required core needle or other surgical pathology specimens.
Patient demographics
Trial participation was offered to 636 patients at 940 unique study encounters, with some patients screened for multiple trials ( Table 1 ). The patients' median age at diagnosis was 61 years (range 18-89 years), 54% were female, 21% were Asian, and 36% had never been smokers.
Trials linked to investigational treatment
In the 54 trials linked to investigational treatment, participants were approached at 549 unique study encounters. There were 447 encounters for trials with mandatory tissue sample requirements and 102 for trials for which tumor tissue was not required (Table 2) . Overall, 60% of patients proceeded to receive study treatment. Patients considering trials without mandatory tissue sample requirements were more likely to receive study treatment than were those considering trials with such requirements (83% versus 55%, p < 0.0001). Furthermore, such patients had a shorter time interval from initial consent to start of treatment (median 9 days versus 16 days, p ¼ 0.002, Table 2 ).
The 447 encounters for studies with mandatory tissue sample requirements included 87 encounters for trials requiring immediate prestudy biopsies. Archival tissue was permitted for the remaining 360 study encounters (Table 2) , with repeat biopsy required only if archival tissue was not available or not suitable for analysis. Patients considering trials permitting use of archival tissue were more likely to receive study treatment than were those considering trials mandating repeat biopsies (59% versus 38%, p ¼ 0.0007). Such patients also had a shorter time interval from initial consent to repeat biopsy than did patients who had mandatory repeat biopsies performed (median 16 days versus 21 days, p ¼ 0.02). Patients in trials permitting use of archival tissue also had a shorter time interval from initial consent to start of treatment (median 14 days versus 54 days, p < 0.001).
Trials with mandatory repeat biopsies
Six trials required mandatory repeat biopsies for integral biomarker analysis that was required before study enrollment. The median time from consent to research biopsy was 21 days (range 12-29 days). Of those patients who were screened, 41 (47%) had confirmation of the biomarker required for enrollment by a central laboratory. However, eight of them were unable to begin the study treatment on account of deteriorating clinical status or the development of other exclusion criteria. For the remaining 33 patients, the median time from consent to initiation of study treatment was 54 days (range 25-117 days).
Barriers to enrollment in trials
The reasons for not proceeding to study treatment are summarized in Table 3 . Of the patients involved in all 549 study encounters (trials linked to treatment), 220 (40%) were unable to proceed to study treatment. The most common barrier to trial enrollment was absence of the required prespecified biomarker (34%). Patients withdrew consent in 20% of encounters or were excluded on the basis of other exclusion criteria such as comorbid conditions or poor performance status (15%). Clinical deterioration or death (17%) after initial study consent had been provided but before study therapy was started were also frequent. Finally, 10% were excluded because of insufficient tissue for molecular analysis (archival or repeat biopsy sample). In total, 128 repeat biopsies were performed. Only one repeat biopsy was performed for a trial in which tumor tissue was optional. The remaining repeat biopsies were performed for trials with mandatory repeat biopsies (n ¼ 68) or for patients who did not have sufficient archival tissue available (n ¼ 59). Six percent of repeat biopsies performed for study had insufficient tissue for analysis. Complications, including pneumothorax (13%) and local bleeding, were seen in 24% of patients; however, only two patients required hospital admission for biopsy-related complications. No patient was excluded from trial participation because of biopsyrelated complications.
A molecular profiling trial was offered at 391 study encounters to patients who had archival core biopsy or resection samples available for analysis. Profiling was successfully completed for 280 patients (72%), with at least one targetable mutation detected in 196 (70%).
Molecular profiling could not be performed for 85 patients (22%) because of insufficient tissue for analysis, and 10 patients (3%) died before completion of molecular profiling. Another 16 patients had pending results at the time of data cutoff.
Discussion
The majority of the trials of therapies for advanced NSCLC that were studied required tumor tissue for enrollment, with substantial attrition among patients screened for trials. Clinically important delays in obtaining repeat biopsy samples and starting treatment also were noted, particularly for trials with mandatory repeat biopsies (in which patients experienced a greater than threefold increase in time to starting study treatment). Complex inclusion criteria and lengthy screening procedures in addition to the logistic challenges of repeat biopsies and analysis by a central laboratory may account for the delays observed. So prolonged a screening process precluded many patients (including eight patients with the desired biomarker status after mandatory repeat biopsy) from receiving study treatment. Biopsy-related complications also resulted in hospitalization of a few patients. The consequences of mandatory tumor tissue requirements in clinical trials of therapies for advanced NSCLC with respect to accrual rates, potential time delays, and patient attrition are sobering for investigators and patients. Patient attitudes toward clinical trials 12, 13 and research biopsies 14 have been studied as barriers to participating in clinical trials. In addition to the challenges they face in overcoming these barriers, patients remain at risk for clinical deterioration from progression of their underlying lung cancer, thus making even small delays highly detrimental. Although investigational therapies often hold great promise of clinical benefit, clinical trials are often the only means for patients to access costly novel therapies (e.g., T790M inhibitors, ALK inhibitors, immune checkpoint agents) with documented efficacy.
Delays arise not only in connection with arranging research biopsies, but also as a result of laboratory analysis and biomarker testing turnaround time. 15 Many clinical trials, particularly industry-sponsored trials, require centralized laboratory testing for confirmation of integral biomarkers and do not allow analysis in accredited local laboratories. In addition, cytology and fine-needle aspirates are often deemed unsuitable for research analysis, even though in many patients, advanced NSCLC is diagnosed by using these techniques and many laboratories have developed techniques for molecular analysis of cytology specimens.
Current clinical trials, particularly those with molecular selection, require repeat biopsies. Although molecular selection contributes significantly to lower trial enrollment rates, repeat tumor sampling contributes also. Repeat biopsy before subsequent targeted therapy is justified in circumstances in which resistance mutations may develop with prior therapy (e.g., T790M inhibitors). Whether analysis of archival tumor tissue is appropriate is thus influenced by the biomarker of interest that is being investigated. Although some of these requirements may be driven by federal regulatory agencies, inflexible requirements regarding tissue acquisition and processing restrict the use of readily available tumor tissue and increase logistic complexity. Furthermore, there is debate over whether patients or institutions have ownership of diagnostic tumor tissue, 16 with some institutions rejecting patient requests for release of their archival diagnostic tissue for research purposes. The impact of such limitations is further magnified in resource-limited settings, such as public health care systems.
Potential limitations of this study include the generalizability of our findings given that our study is limited to a single quaternary referral center with an established clinical trials program. We also do not know how many patients may have been considered for clinical trial participation but were never approached because of a lack of the required archival tissue and reluctance on the part of investigators to delay treatment to allow obtaining additional tissue. Finally, we were not able to evaluate the impact of tissue requirements and delays in study enrollment and treatment on patient survival, given the potential for inherent selection bias. The constraints of conducting research in a publicly funded health care system with significant resource limitations may also restrict the generalizability of our findings to jurisdictions without such resource limitations (e.g., biopsy availability).
Despite these potential limitations, our study identifies a need to reevaluate the role of research biopsies in clinical trials and implement solutions that will improve patient access to investigational treatment by addressing mandatory tumor tissue requirements. Implementing routine tissue banking at diagnosis, obtaining larger diagnostic samples, and facilitating use of available diagnostic specimens (e.g., cytology samples) for trials may reduce the need for repeat biopsies and enhance patient enrollment. Several studies have demonstrated good correlation between small biopsy or cytology samples and resection specimens for molecular biomarkers of current interest, including EGFR mutation and programmed cell death-ligand 1 gene (PD-L1) status. 5, 17 Development of peripheral blood assays, such as circulating tumor DNA or other assays, for trials may eliminate or reduce the need for research biopsies. 6 Faster turnaround time for centralized biomarker testing could also mitigate delays in starting study therapy, as could greater use of accredited local laboratory results. Finally, more resources dedicated to tissue acquisition for research purposes, in addition to resources for clinical diagnosis, are needed to ensure timely access to research biopsies and research for cancer patients.
Conclusions
A growing number of trials of therapies for advanced NSCLC are requiring tumor tissue for treatment eligibility, thus adding to the complexity of trial design as patient selection becomes increasingly driven by molecular analysis of tumor tissue. Molecular selection was the most common cause of trial ineligibility in our study; however, the requirement for additional tumor tissue poses a significant barrier to clinical trial enrollment, with repeat biopsies, tissue acquisition, and central biomarker testing resulting in significant delays in initiating study treatment and in patient attrition. Potential solutions include routine tissue banking at diagnosis, facilitation of the use of available diagnostic samples for trials, development of peripheral blood assays for trials, faster central laboratory turnaround time or permission for accredited local testing, and more resources for timely acquisition of tissue for clinical trials.
